Andrew A. Protter, Ph.D.

Vice President, Preclinical Development

Dr. Protter joined Medivation in September 2006 following a 24-year career at Scios, Inc., where he served most recently as vice president, biology. At Scios, which was acquired in 2003 by Johnson & Johnson, Dr. Protter had responsibility for all preclinical development activities for Natrecor®, a recombinant protein approved by the FDA in 2001 to treat acute decompensated heart failure, and for multiple small-molecule product candidates. In recognition of his work, Dr. Protter was awarded the 2004 Johnson Medal for Natrecor research and development. Dr. Protter has published extensively in the fields of natriuretic peptides, lipid transport and intracellular kinases regulating inflammation, pain and fibrosis. He received a Ph.D. in biochemistry from the State University of New York, Stony Brook.

Top